Top Stories: Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), Westell Technologies, Inc. (NASDAQ:WSTL), Portola Pharmaceuticals, Inc. (NASDAQ:PTLA), ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), Gogo Inc. (NASDAQ:GOGO)

Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE) belongs to Healthcare sector. Its weekly performance is -21.46%. On last trading day company shares ended up $12.33. Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE) distance from 50-day simple moving average (SMA50) is -7.94%. On 29 June, Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE) announced top-line clinical efficacy results from the metformin arm of an ongoing Phase 2 proof-of-concept clinical trial of BI187004/VTP-34072 in the treatment of overweight type 2 diabetic patients. BI187004/VTP-34072 is a potential first-in-class 11β-hydroxysteroid dehydrogenase type 1 (11β HSD1) inhibitor that was discovered by Vitae and is currently being developed by Boehringer Ingelheim GmbH (Boehringer Ingelheim), a leader in diabetes treatments and cardiometabolic research and development.

Westell Technologies, Inc. (NASDAQ:WSTL) belongs to Technology sector. Its net profit margin is -68.80% and weekly performance is 4.04%. On last trading day company shares ended up $1.03. Westell Technologies, Inc. (NASDAQ:WSTL) distance from 50-day simple moving average (SMA50) is -10.56%. On 25 June, Westell Technologies, Inc. (NASDAQ:WSTL) announced the introduction of its ClearLink® DAS. ClearLink DAS is an advanced in-building distributed antenna system (DAS) used to enhance high-speed cellular technologies, such as LTE, and provide outstanding coverage with superior data rates within buildings.

Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) shares decreased -0.17% in last trading session and ended the day at $45.85. PTLA return on assets is -41.60%. Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) quarterly performance is 23.12%. On 24 June, Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) announced results of a study demonstrating that andexanet alfa significantly reduced bleeding in a validated animal model of bleeding using the Factor Xa inhibitor rivaroxaban as the anticoagulant.

On 02 July, ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) shares increased 0.05% and was closed at $41.69. ACAD EPS growth in last 5 year was 4.60%. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) year to date (YTD) performance is 31.31%. Zacks upgraded shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) from a sell rating to a hold rating in a research report sent to investors on Thursday morning.

Gogo Inc. (NASDAQ:GOGO) ended the last trading day at $21.34. Company weekly volatility is calculated as 5.63% and price to cash ratio as 4.57. Gogo Inc. (NASDAQ:GOGO) showed a weekly performance of -7.86%. On 26 June, Gogo Inc. (NASDAQ:GOGO) said that it now expects full year adjusted EBITDA at the higher end of its previously announced range. Investors reacted positively to the news as shares jumped 6.1% in the last trading session, touching a day high of $23.20, before closing a notch lower at $23.16

Leave a Reply

Your email address will not be published. Required fields are marked *